Intermediary stadium of Hodgkin’s lymphoma – citius, altius, or fortius? – editorial
Authors:
D. Feltl 1; J. Marková 2
Authors‘ workplace:
Radioterapeutická klinika Fakultní nemocnice s poliklinikou, Ostrava, přednosta prim. MUDr. David Feltl, Ph. D.
1; Oddělení klinické hematologie FN Královské Vinohrady, Praha, přednosta doc. MUDr. Tomáš Kozák, Ph. D.
2
Published in:
Vnitř Lék 2007; 53(1): 7-8
Category:
Editorials
Sources
1. Ng AK, Bernardo MV, Weller E et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002; 20: 2101-2108.
*2. Carde P, Cavalli R, Diehl V et al. Treatment of advanced Hodgkin’s disease: is there a standard therapy? The Hematology Journal 2000; 1: 282-290.*
3. Horning SJ, Hoppe RT, Breslin J et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 3: 630-637.
4. Yahalom J. Don't throw out the baby with the bathwater: on optimizing cure and reducing toxicity in Hodgkin's lymphoma. J Clin Oncol 2006; 24: 544-548.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2007 Issue 1
Most read in this issue
- The FEVER (Felodipine EVEnt Reduction) trial; a randomised, double-blind, placebo-controlled trial in Chinese hypertensive patients
- Guidelines for pharmacotherapy of acute and chronic non-oncological pain
- Epilepsy and disorders of reproduction
- The importance of determination of Nt-proBNP and big endothelin in diagnosing chronic heart failure in patients on regular haemodialysis treatment